Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
72 studies found for:    Paraneoplastic Syndromes
Show Display Options
Rank Status Study
1 Completed
Has Results
Immunotherapy of the Paraneoplastic Syndromes
Condition: Paraneoplastic Syndromes
Intervention: Drug: Tacrolimus
2 Completed Studies of Neurological Paraneoplastic Syndromes
Condition: Paraneoplastic Neurologic Degenerations (PNDs)
Intervention:
3 Recruiting The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
Condition: Paraneoplastic Syndromes
Intervention:
4 Recruiting Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia
Condition: Hypophosphatemia
Intervention:
5 Unknown  Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome
Condition: Opsoclonus-myoclonus Syndrome
Intervention:
6 Active, not recruiting Immunotherapy and Paraneoplastic Neurological Syndromes
Condition: Paraneoplastic Neurological Syndromes
Intervention: Drug: Immunoglobulin
7 Completed
Has Results
One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
Conditions: Osteoporosis;   Humoral Hypercalcemia of Malignancy;   Hyperparathyroidism
Intervention: Drug: PTHrP (1-36)
8 Unknown  Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: zoledronic acid;   Procedure: quality-of-life assessment
9 Unknown  Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer
Interventions: Drug: ibandronate sodium;   Drug: zoledronic acid;   Drug: Zolendronic Acid
10 Withdrawn S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer;   Pain
Interventions: Drug: ibandronate;   Drug: zoledronate;   Procedure: quality-of-life assessment
11 Completed Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Conditions: Breast Cancer;   Hypercalcemia of Malignancy;   Metastatic Cancer;   Pain
Interventions: Biological: monoclonal antibody CAL;   Drug: zoledronic acid
12 Completed Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
Conditions: Hypercalcemia of Malignancy;   Lung Cancer;   Metastatic Cancer;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: zoledronic acid;   Procedure: quality-of-life assessment
13 Completed Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
Condition: Congenital Myasthenic Syndrome
Intervention: Drug: Albuterol
14 Available Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
15 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP
16 Unknown  Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Conditions: Lambert-Eaton Myasthenic Syndrome;   Eaton-Lambert Myasthenic Syndrome
Interventions: Drug: 3,4-DAP;   Drug: 3,4-DAP Taper to Placebo
17 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
18 Recruiting 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome
Interventions: Drug: 3,4-DIAMINOPYRIDINE;   Drug: 3,4-Diaminopyridine
19 Completed A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate;   Drug: Placebo
20 No longer available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.